Spanish firm Grifols to spend a total of $360 million on four new plants
pharmafile | March 11, 2016 | News story | Manufacturing and Production, Medical Communications | grifols, manufacturing, pharma, plasma, production
Grifols (Nasdaq: GRFS) said it will invest a total of $360 million over 2016-2021, to increase the plasma fractionation capacity and purification of the several proteins.
The investment is for the company’s bioscience unit with the goal of expanding the manufacturing capacity to cover the expected growing demand of plasma-derived products for the upcoming years, the company said in a statement.
Grifols is engaged in the manufacturing of plasma-based medicines with direct commercial presence in 30 countries and sales in over 100.
About $201 million off the total will be spent to construct two new plants in Clayton, US. The construction of the first plasma fractionation plant will begin in the first quarter of 2017 and is scheduled to start production in early 2022. The facility will be used to extract proteins with therapeutic uses.
The second plant will be a purification facility for intravenous immunoglobin. It is scheduled to begin operating in late 2021.
The Barcelona-based company has already invested more than $370 million in its Clayton plasma plant since 2010. In addition, the company is constructing a plasma warehousing center in Clayton to handle the increased supply of plasma that its new fractionation plant will require. The plant will have a capacity of 3.7 million liters, and is scheduled to be fully operational by the end of 2016.
The company will open 75 new centers with the aim of bringing the total number of centers up to 225 by 2021. The company currently has 160 operating centers.
In addition, Grifols has planned to construct a third testing laboratory to handle the increased number of samples, mainly, from these 75 new plasma centers. It is expected to come into operation by 2019.
Anjali Shukla
Related Content
Lonza to acquire biologics site in Vacaville, US from Roche for $1.2bn
Lonza has announced that it has signed an agreement to acquire the Genentech large-scale biologics …
AbbVie invests $223m in Singapore manufacturing site
AbbVie has announced that it has invested $223m in an expansion to its Singapore manufacturing …
DelSiTech announces closing of €10m financing round for silica-based drug delivery platform
DelSiTech has announced the successful completion of a €10m financing round, marking the largest single …
